Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-020206

CHIEF SCIENTIFIC OFFICER sold 12,500 shares at an average $22.29 ($278,646)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2025-07-21 Sale : show line 1 in the form 10b5-1 −11,924 $22.26 $265,458 953,264 I
2025-07-21 Sale : show line 2 in the form 10b5-1 −576 $22.90 $13,188 952,688 I
Open-market sales · 12,500 sh · avg $22.29 · $278,646
Loading xslF345X05/form4-07232025_100717.xml…